Mimotopes Pty. Ltd. and GlycoSyn IRL are Awarded NZ $715,000 to Build Specialist GMP Peptide Capabilities

MELBOURNE, Australia, & LOWER HUTT, New Zealand--(BUSINESS WIRE)--Mimotopes Pty Ltd, a subsidiary of Commonwealth Biotechnologies Inc, Richmond, VA (Nasdaq Capital Market: CBTE), and GlycoSyn, a business unit of IRL Ltd, were today awarded NZ $715,000 from New Zealand Trade and Enterprise (NZTE) through the Australia New Zealand Biotechnology Partnership Fund to develop the Southern Hemisphere’s only specialist small molecule and peptide manufacturing facility operating under conditions of Good Manufacturing Practice (GMP). The joint initiative, utilizing Mimotopes’ peptide expertise and proprietary synthesis platform and GlycoSyn’s stringent quality control systems, meets the expanding needs of the global biotechnology industry for custom-synthesized peptide therapeutic candidates.